Melbourne, Sep 3, 2010 (ABN Newswire) - Benitec Limited (
ASX:BLT) (PINK:BNIKF), a leading Australian based company specialising in RNA interference (RNAi) technology, is pleased to announce a strategy update and broadening of its R&D pipeline following the recent Board and management changes announced earlier this year.
Until recently Benitec's research focus was solely based on its HIV/AIDS program at City of Hope in Duarte, California. Following encouraging Phase I results from the HIV/AIDS stem cell trial using a triple RNA-based construct, conducted by researchers at City of Hope and recently published in Science Translational Medicine, Benitec is now committed to further demonstrating the power of its ddRNAi technology for gene silencing in a variety of diseases, including hepatitis B, non-small cell lung cancer, hepatitis C (licensed to Tacere Therapeutics) and HIV/AIDS.
Benitec CEO, Dr Peter French said: "Benitec has a growing pipeline of valuable assets backed by a strong IP position. The Company is entering an exciting new era, using its predominant patent position in RNAi to build a broad portfolio of clinical and pre-clinical programs to demonstrate the power and the range of its ddRNAi technology."
A previously announced pilot study of safety and feasibility of using the same construct to transfect T cells in HIV/AIDS patients who have failed HAART therapy has been put on hold primarily due to patient recruitment challenges arising from the trial's eligibility requirements. Benitec and City of Hope are now in discussions to redesign the program with an objective of partnering or out-licensing the program to an industry partner with an interest in HIV/AIDS therapeutics.
ASX:BLT) (PINK:BNIKF), a leading Australian based company specialising in RNA interference (RNAi) technology, is pleased to announce a strategy update and broadening of its R&D pipeline following the recent Board and management changes announced earlier this year.Until recently Benitec's research focus was solely based on its HIV/AIDS program at City of Hope in Duarte, California. Following encouraging Phase I results from the HIV/AIDS stem cell trial using a triple RNA-based construct, conducted by researchers at City of Hope and recently published in Science Translational Medicine, Benitec is now committed to further demonstrating the power of its ddRNAi technology for gene silencing in a variety of diseases, including hepatitis B, non-small cell lung cancer, hepatitis C (licensed to Tacere Therapeutics) and HIV/AIDS.
Benitec CEO, Dr Peter French said: "Benitec has a growing pipeline of valuable assets backed by a strong IP position. The Company is entering an exciting new era, using its predominant patent position in RNAi to build a broad portfolio of clinical and pre-clinical programs to demonstrate the power and the range of its ddRNAi technology."
A previously announced pilot study of safety and feasibility of using the same construct to transfect T cells in HIV/AIDS patients who have failed HAART therapy has been put on hold primarily due to patient recruitment challenges arising from the trial's eligibility requirements. Benitec and City of Hope are now in discussions to redesign the program with an objective of partnering or out-licensing the program to an industry partner with an interest in HIV/AIDS therapeutics.
About Benitec Limited
Benitec Limited (ASX:BLT) (PINK:BNIKF) holds a dominant position in expressed RNA interference (RNAi)-based human therapeutics, with a transformational platform technology supported by a robust and extensive intellectual property portfolio. Benitec is leveraging this platform to develop and build a pipeline of expressed RNAi therapeutics focusing on treatment and alleviation of cancer and infectious disease. With strong global partnerships and committed scientific and clinical investigators, Benitec Ltd aims to deliver a range of novel RNAi-based therapeutics to the clinic in partnership with the pharmaceutical industry.
|
||
|
 |
Related Companies |
>>>       Benitec Limited |
| |
Related Industry Topics: |
Biotech | Drugs & OTC | Financial General | Health & Pharm General | |
| |
This Page Viewed: (Last 7 Days: 20) (Last 30 Days: 80) (Since Published: 13480) |
Events & Exhibitions
|
Site Search
| ENGLISH All Languages |
AJAX UNION |
|||
|
|||
Companies in the News
ABN Newswire on iPhone/iPad
|
| Download from Apple |
Mobile Video TV
|
||
|
||
){kind=link}